The Endometriosis pipeline report provides detailed information of the Endometriosis pipeline products from the initial phase of product development until its commercialisation in the Endometriosis market.

Endometriosis Pipeline Drug Insights Report 2025

Endometriosis Pipeline Infographic

DelveInsight&rsquo;s, &ldquo;Endometriosis - Pipeline Insight, 2025&rdquo; report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Endometriosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
&nbsp;
<h3>Geography Covered</h3>
<ul>
<li>Global coverage</li>
</ul>
&nbsp;
<h3>Endometriosis: Understanding</h3>
Endometriosis: Overview
Endometriosis is defined as the presence of endometrial glands and stroma like lesions outside of the uterus. The lesions can be peritoneal lesions, superficial implants or cysts on the ovary, or deep infiltrating disease. While there is no definitive etiology of endometriosis, there are several hypotheses regarding how endometriotic lesions develop. One possible mechanism is retrograde menstruation, a feature of the menstrual cycle in women and non-human primates, which is an outflow of the endometrial lining through the patent fallopian tubes into the pelvic space. This retrograde flow, along with potential hematogenous or lymphatic circulation, may result in the seeding of endometrial tissue in ectopic sites. However, retrograde menstruation is common (perhaps universal among menstruating women) while endometriosis is much less common. Therefore, other factors, such as hormonal, inflammatory, or immunologic milieu may determine whether lesions deposited in the pelvic cavity implant and persist. Alternatively, endometriosis lesions may arise from M&uuml;llerian remnants that did not properly differentiate or migrate during fetal development or from circulating blood cells that transdifferentiate into endometriosis.
&nbsp;
Endometriosis is a long-term, often misunderstood condition that manifests through a variety of distressing physical symptoms, most notably intense menstrual cramps, chronic pelvic pain, and complications with fertility, which can be emotionally and physically exhausting. Beyond the physical burden, the condition takes a profound toll on mental health, with many women experiencing elevated levels of depression, anxiety, and a diminished overall quality of life as they navigate the daily challenges of living with persistent pain and uncertainty. The diagnostic journey is frequently prolonged, sometimes taking years, during which patients may encounter medical professionals who minimize or dismiss their experiences, adding layers of frustration, isolation, and psychological distress. This combination of enduring pain, delayed diagnosis, and emotional invalidation contributes to a deeply challenging reality for those affected, highlighting the urgent need for greater awareness, faster diagnosis, and more compassionate, comprehensive care.
&nbsp;
Endometriosis is a chronic, inflammatory condition that presents a significant diagnostic challenge due to its wide range of variable and often non-specific symptoms, which can mimic other disorders and contribute to prolonged delays in diagnosis. Identifying the condition typically requires a multifaceted approach, including a thorough clinical history, physical examination, and imaging techniques such as transvaginal ultrasound, though these methods may not always detect the presence or extent of the disease. Despite advances in non-invasive diagnostics, the gold standard for confirming endometriosis remains laparoscopic surgery, which allows for direct visualization and biopsy of endometrial lesions, making it an essential but invasive step in securing a definitive diagnosis. Timely detection and intervention are vital for effectively managing symptoms, preserving fertility, and reducing the risk of long-term complications such as chronic pelvic pain and organ damage. However, due to the elusive and often misunderstood nature of the disease, many individuals endure an average delay of seven years before receiving a formal diagnosis, underscoring the need for increased awareness, improved diagnostic tools, and greater clinical sensitivity.&nbsp;
&nbsp;
The treatment and management of endometriosis involves a combination of medical and surgical approaches. Medical therapies aim to control pain and suppress the growth of endometrial lesions, and include options like non-steroidal anti-inflammatory drugs, oral contraceptives, progestogens, GnRH agonists, and aromatase inhibitors. For women who do not respond to medical therapy or have severe symptoms, surgical excision of endometrial lesions and adhesions can provide confirmatory diagnosis and symptom relief. Early diagnosis and a multidisciplinary approach involving gynecologists, pain specialists, and other healthcare providers are crucial to effectively manage this chronic, debilitating condition.
&nbsp;
"Endometriosis- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometriosis pipeline landscape is provided which includes the disease overview and Endometriosis treatment guidelines. The assessment part of the report embraces, in depth Endometriosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometriosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
&nbsp;
<h3>Report Highlights</h3>
<ul>
<li>The companies and academics are working to assess challenges and seek opportunities that could influence Endometriosis R&amp;D. The therapies under development are focused on novel approaches to treat/improve Endometriosis.</li>
</ul>
&nbsp;
<h3>Endometriosis Emerging Drugs Chapters</h3>
This segment of the Endometriosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
&nbsp;
Endometriosis Emerging Drugs
<ul>
<li>HMI-115: Hope Medicine</li>
</ul>
HMI-115 is a first-in-class monoclonal antibody drug that is developed by Hope Medicine Inc. that targets the prolactin receptor, a novel mechanism implicated in various hormone-related conditions. Designed to modulate prolactin signaling, HMI-115 holds therapeutic potential across multiple indications, including endometriosis and androgenetic alopecia. By specifically blocking the prolactin receptor, it aims to address underlying disease mechanisms without disrupting the broader hormonal balance, offering a targeted and innovative approach to treatment. Currently, the drug is in Phase II stage of its clinical development for the treatment of Endometriosis.
&nbsp;
<ul>
<li>Merigolix: TiumBio</li>
</ul>
TU2670 is an oral GnRH antagonist that can bind to pituitary receptors to suppress estradiol hormone. The existing treatment GnRH agonists, lowers patient comfort levels as it&rsquo;s in an injection form and inhibits sex hormones to the level of menopause, resulting in serious side effects such as bone loss. TU2670 is an oral GnRH antagonist that only suppresses hormone levels to the level of efficacy, improving both side effects and ease of administration by oral. In addition, being a sex hormone control mechanism, it allows for indication expansion to precocious puberty, test-tube baby, infertility treatment, etc. Currently, the drug is in Phase II stage of its development for the treatment of Endometriosis.
&nbsp;
<ul>
<li>SHR7280: Jiangsu HengRui Medicine Co., Ltd</li>
</ul>
SHR7280 is an orally bioavailable Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, GnRH antagonist SHR7280 competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In females, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases. Since SHR7280 reduces the occurrence of premature LH surge in females, premature ovulation is also prevented. Currently, the drug is in Phase I/II stage of its development for the treatment of Endometriosis.
Further product details are provided in the report&hellip;&hellip;..
&nbsp;
<h3>Endometriosis: Therapeutic Assessment</h3>
This segment of the report provides insights about the different Endometriosis drugs segregated based on following parameters that define the scope of the report, such as:
Major&nbsp; Players in Endometriosis
There are approx. 18+ key companies which are developing the therapies for Endometriosis. The companies which have their Endometriosis drug candidates in the most advanced stage, i.e. Phase II include, Hope Medicine.
&nbsp;
Phases
DelveInsight&rsquo;s report covers around 20+ products under different phases of clinical development like
<ul>
<li>Late stage products (Phase III)</li>
<li>Mid-stage products (Phase II)</li>
<li>Early-stage product (Phase I) along with the details of&nbsp;</li>
<li>Pre-clinical and Discovery stage candidates</li>
<li>Discontinued &amp; Inactive candidates</li>
</ul>
&nbsp;
Route of Administration
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as&nbsp;
<ul>
<li>Oral</li>
<li>Intravenous</li>
<li>Subcutaneous</li>
<li>Parenteral&nbsp;</li>
<li>Topical</li>
</ul>
&nbsp;
Molecule Type
Products have been categorized under various Molecule types such as
<ul>
<li>Recombinant fusion proteins</li>
<li>Small molecule</li>
<li>Monoclonal antibody</li>
<li>Peptide</li>
<li>Polymer&nbsp;</li>
<li>Gene therapy</li>
</ul>
&nbsp;
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
&nbsp;
<h3>Endometriosis: Pipeline Development Activities&nbsp;</h3>
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Endometriosis therapeutic drugs key players involved in developing key drugs.&nbsp;
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometriosis drugs.
&nbsp;
<h3>Endometriosis Report Insights</h3>
<ul>
<li>Endometriosis Pipeline Analysis</li>
<li>Therapeutic Assessment</li>
<li>Unmet Needs</li>
<li>Impact of Drugs</li>
</ul>
&nbsp;
<h3>Endometriosis Report Assessment</h3>
<ul>
<li>Pipeline Product Profiles</li>
<li>Therapeutic Assessment</li>
<li>Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
&nbsp;
Key Questions
Current Treatment Scenario and Emerging Therapies:
<ul>
<li>How many companies are developing Endometriosis drugs?</li>
<li>How many Endometriosis drugs are developed by each company?</li>
<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometriosis?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Endometriosis therapeutics?&nbsp;</li>
<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?&nbsp;</li>
<li>What are the clinical studies going on for Endometriosis and their status?</li>
<li>What are the key designations that have been granted to the emerging drugs?</li>
</ul>

Introduction
Executive Summary
Endometriosis: Overview
<ul>
<li>Introduction</li>
<li>Causes</li>
<li>Pathophysiology&nbsp;</li>
<li>Signs and Symptoms</li>
<li>Diagnosis</li>
<li>Treatment</li>
</ul>
Pipeline Therapeutics
<ul>
<li>Comparative Analysis</li>
</ul>
Therapeutic Assessment
<ul>
<li>Assessment by Product Type</li>
<li>Assessment by Stage and Product Type</li>
<li>Assessment by Route of Administration</li>
<li>Assessment by Stage and Route of Administration</li>
<li>Assessment by Molecule Type</li>
<li>Assessment by Stage and Molecule Type&nbsp;</li>
</ul>
Endometriosis&ndash; DelveInsight&rsquo;s Analytical Perspective
Late Stage Products (Phase III)
<ul>
<li>Comparative Analysis</li>
</ul>
Drug Name: Company Name
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
&nbsp;
Mid Stage Products (Phase II)
<ul>
<li>Comparative Analysis</li>
</ul>
HMI-115: Hope Medicine
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
&nbsp;
Early Stage Products (Phase I/II)&nbsp;
<ul>
<li>Comparative Analysis</li>
</ul>
SHR7280: Jiangsu HengRui Medicine Co., Ltd
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
&nbsp;
Preclinical and Discovery Stage Products&nbsp;
<ul>
<li>Comparative Analysis</li>
</ul>
Drug Name: Company Name
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
&nbsp;
Inactive Products
<ul>
<li>Comparative Analysis</li>
</ul>
Endometriosis Key Companies
Endometriosis Key Products
Endometriosis- Unmet Needs
Endometriosis- Market Drivers and Barriers
Endometriosis- Future Perspectives and Conclusion
Endometriosis Analyst Views
Endometriosis Key Companies
Appendix

DelveInsight’s, “Endometriosis – Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Endometriosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.  

Endometriosis - Pipeline Insight, 2025

Endometriosis Pipeline Insights, 2025 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Endometriosis market.